[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100575425":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":24,"centralContacts":31,"locations":10,"responsibleParty":41,"collaborators":43,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":48,"sex":54,"minAge":10,"maxAge":10,"enrollmentInfo":55,"targetDuration":58,"studyType":59,"phases":10,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":72,"whyStopped":10,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":10},{"fullName":5,"class":6},"Institut Mutualiste Montsouris","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with intermediate-risk prostate cancer",null,"he study includes patients with intermediate-risk prostate cancer (PCa), as defined by the European Association of Urology (EAU) risk groups, and a life expectancy of more than 10 years. Eligible patients must have undergone both targeted and systematic biopsies confirmed through the US-MRI fusion technique. All participants are required to provide informed, written consent before being included in the study.",[13],"Procedure: Focal Therapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"PROCEDURE","Focal Therapy","Primary focal treatment (targeted or partial gland ablation) of PCa lesion(s) detected on mpMRI, where a PCa ISUP 2 or 3 has been identified (PCa ISUP 1 outside the treatment areas is acceptable, regardless of volume).\n\nFocal treatment will be performed using one of the following energy-based techniques: high-intensity focused ultrasound (HIFU), cryotherapy (CRYO), brachytherapy (BT), irreversible electroporation (IRE), focal laser ablation (FLA), vascular-targeted photodynamic therapy (VTP), or radiofrequency ablation (RFA). The specific technique will depend on the rules, approvals, and regulations of the country where the treatment is performed.",[9],[21,22,23],"Targeted Therapy for Prostate Cancer","Partial Gland Ablation (PGA)","Energy-Based Ablative Therapy",[25,28],{"name":26,"affiliation":5,"role":27},"Eric Barret, MD, PhD","PRINCIPAL_INVESTIGATOR",{"name":29,"affiliation":30,"role":27},"Juan I Martinéz-Salamanca, MD, PhD","Lyx Institute of Urology",[32,37],{"name":33,"role":34,"phone":35,"phoneExt":10,"email":36},"Giuseppe Maiolino, MD","CONTACT","+39 3204066478","jupiter.registry@gmail.com",{"name":38,"role":34,"phone":39,"phoneExt":10,"email":40},"Andrea Rodríguez Serrano, MD","+34 609 10 60 08","andrearodriguezserrano@hotmail.com",{"type":42,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[44],{"name":45,"class":6},"European Association of Urology Research Foundation","100575425","focal-therapy-in-localized-prostate-cancer-a-prospective-registry-100575425",false,"NCT06772116","Focal Therapy in Localized Prostate Cancer: a Prospective Registry","Jupiter Registry: Prospective Registry for Patients Undergoing Focal Therapy for Localized Prostate Cancer","JR","Inclusion Criteria:\n\n* Patients with intermediate risk PCa based on EAU risk groups with life expectancy \\> 10 years\n* Prior targeted + systematic biopsy using US-MRI fusion technique\n* Primary focal treatment (targeted or partial gland ablation) of PCa lesion(s) detected on mpMRI, where PCa ISUP 2 or 3 has been identified. PCa ISUP 1 outside the treatment areas is acceptable, regardless of volume.\n* Focal treatment was performed using one of the following energies: high-intensity focused ultrasound (HIFU), cryotherapy (CRYO), brachytherapy (BT), irreversible electroporation (IRE), focal laser ablation (FLA), vascular-targeted Photodynamic (VTP) and radiofrequency ablation (RFA) according to the country rules, approvals, and regulations of each country in which they are applied. The registry cannot be used as a clinical trial or post-marketing surveillance study of the technologies applied.\n* Free, informed and written consent\n\nExclusion Criteria:\n\n* Patients with intermediate risk treated with focal therapy without a previous targeted + systematic prostate biopsy with US-MRI fusion technique.\n* Primary focal treatment of PCa ISUP 2 or 3 in areas of prostate without evidence of lesions on MRI (MRI-invisible prostate cancer)\n* Patients with histological diagnosis of PCa with ISUP \\> 1 outside the areas of treatment\n* Primary whole gland treatments using ablative energy HIFU, cryotherapy, IRE, FLA, VTP and\u002For RFA\n* Primary subtotal\u002Ftotal treatments using ablative energy HIFU, cryotherapy, IRE, FLA, VTP and\u002For RFA\n* Life expectancy \\\u003C10 years\n* Previous treatment of PCa (excluded a period of Active Surveillance)\n* High risk PCa based on EAU risk groups.\n* Locally advanced PCa\n* Metastatic hormone-sensitive prostate cancer (mHSPC)\n* Metastatic castration-resistant prostate cancer (mCRPC)\n* Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)","MALE",{"count":56,"type":57},1000,"ESTIMATED","5 Years","OBSERVATIONAL","The principal aim of the registry is to collect data on focal therapy (FT) for the treatment of intermediate-risk prostate cancer across Europe. Data will be gathered on cancer absence following treatment, survival rates, and the absence of disease failure or progression. Information will be collected from as many centers as possible over the next 5 years to enhance understanding of when focal therapy should be used, which energy types are most effective, and how patients respond to treatment, including its side effects and impact on quality of life.\n\nThis Europe-wide data collection will contribute to improving care by informing the development of enhanced national and international guidelines for prostate cancer treatment with focal therapy.",[62,63],"Prostate","Prostate Cancer",[17,65,66,67,68,69,70,71],"HIFU","Cryotherapy","FLA","Focal Brachytherapy","IRE","VTP","RFA","NOT_YET_RECRUITING","2025-01-08",{"date":75,"type":76},"2025-01-13","ACTUAL",{"date":78,"type":57},"2025-02",{"date":80,"type":57},"2032-02",{"name":5,"class":6}]